JP2019517463A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019517463A5 JP2019517463A5 JP2018559929A JP2018559929A JP2019517463A5 JP 2019517463 A5 JP2019517463 A5 JP 2019517463A5 JP 2018559929 A JP2018559929 A JP 2018559929A JP 2018559929 A JP2018559929 A JP 2018559929A JP 2019517463 A5 JP2019517463 A5 JP 2019517463A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- oxopyridin
- methoxypyridin
- methoxymethyl
- pyrazole
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 20
- 239000013078 crystal Substances 0.000 claims 19
- -1 3-Fluoro-4-methoxypyridin-2-yl Chemical group 0.000 claims 17
- 238000000034 method Methods 0.000 claims 13
- 239000000203 mixture Substances 0.000 claims 12
- 239000002904 solvent Substances 0.000 claims 12
- 239000008194 pharmaceutical composition Substances 0.000 claims 11
- ZVXKYWHJBYIYNI-UHFFFAOYSA-N 1h-pyrazole-4-carboxamide Chemical compound NC(=O)C=1C=NNC=1 ZVXKYWHJBYIYNI-UHFFFAOYSA-N 0.000 claims 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical group CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 9
- 102000003827 Plasma Kallikrein Human genes 0.000 claims 7
- 108090000113 Plasma Kallikrein Proteins 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 230000001404 mediated effect Effects 0.000 claims 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 7
- 238000000634 powder X-ray diffraction Methods 0.000 claims 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 5
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 4
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 4
- 230000001351 cycling effect Effects 0.000 claims 4
- 201000011190 diabetic macular edema Diseases 0.000 claims 4
- 206010019860 Hereditary angioedema Diseases 0.000 claims 3
- 230000002207 retinal effect Effects 0.000 claims 3
- 229910021653 sulphate ion Inorganic materials 0.000 claims 3
- 230000008728 vascular permeability Effects 0.000 claims 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 208000031229 Cardiomyopathies Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000001953 Hypotension Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 206010051077 Post procedural haemorrhage Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 206010047571 Visual impairment Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 206010003246 arthritis Diseases 0.000 claims 1
- 230000023555 blood coagulation Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000002612 cardiopulmonary effect Effects 0.000 claims 1
- 238000002425 crystallisation Methods 0.000 claims 1
- 230000008025 crystallization Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 208000009190 disseminated intravascular coagulation Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000036543 hypotension Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 201000001119 neuropathy Diseases 0.000 claims 1
- 230000007823 neuropathy Effects 0.000 claims 1
- 208000033808 peripheral neuropathy Diseases 0.000 claims 1
- 208000004644 retinal vein occlusion Diseases 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 238000000527 sonication Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 208000029257 vision disease Diseases 0.000 claims 1
- 230000004393 visual impairment Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021164519A JP7383676B2 (ja) | 2016-06-01 | 2021-10-06 | カリクレインインヒビターとしての、ｎ－［（３－フルオロ－４－メトキシピリジン－２－イル）メチル］－３－（メトキシメチル）－１－（｛４－［（２－オキソピリジン－１－イル）メチル］フェニル｝メチル）ピラゾール－４－カルボキサミドの多形体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344059P | 2016-06-01 | 2016-06-01 | |
| GBGB1609607.5A GB201609607D0 (en) | 2016-06-01 | 2016-06-01 | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB1609607.5 | 2016-06-01 | ||
| US62/344,059 | 2016-06-01 | ||
| PCT/GB2017/051579 WO2017208005A1 (en) | 2016-06-01 | 2017-06-01 | Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1 -({4-[2-oxopyridin-1 -yl)methyl]phenyl} methyl) pyrazole -4-carboxamide as kallikrein inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164519A Division JP7383676B2 (ja) | 2016-06-01 | 2021-10-06 | カリクレインインヒビターとしての、ｎ－［（３－フルオロ－４－メトキシピリジン－２－イル）メチル］－３－（メトキシメチル）－１－（｛４－［（２－オキソピリジン－１－イル）メチル］フェニル｝メチル）ピラゾール－４－カルボキサミドの多形体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019517463A JP2019517463A (ja) | 2019-06-24 |
| JP2019517463A5 true JP2019517463A5 (enExample) | 2020-07-09 |
| JP6957516B2 JP6957516B2 (ja) | 2021-11-02 |
Family
ID=56410856
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018559929A Active JP6957516B2 (ja) | 2016-06-01 | 2017-06-01 | カリクレインインヒビターとしての、ｎ−［（３−フルオロ−４−メトキシピリジン−２−イル）メチル］−３−（メトキシメチル）−１−（｛４−［（２−オキソピリジン−１−イル）メチル］フェニル｝メチル）ピラゾール−４−カルボキサミドの多形体 |
| JP2021164519A Active JP7383676B2 (ja) | 2016-06-01 | 2021-10-06 | カリクレインインヒビターとしての、ｎ－［（３－フルオロ－４－メトキシピリジン－２－イル）メチル］－３－（メトキシメチル）－１－（｛４－［（２－オキソピリジン－１－イル）メチル］フェニル｝メチル）ピラゾール－４－カルボキサミドの多形体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021164519A Active JP7383676B2 (ja) | 2016-06-01 | 2021-10-06 | カリクレインインヒビターとしての、ｎ－［（３－フルオロ－４－メトキシピリジン－２－イル）メチル］－３－（メトキシメチル）－１－（｛４－［（２－オキソピリジン－１－イル）メチル］フェニル｝メチル）ピラゾール－４－カルボキサミドの多形体 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11230537B2 (enExample) |
| EP (2) | EP4151630A1 (enExample) |
| JP (2) | JP6957516B2 (enExample) |
| KR (1) | KR102425918B1 (enExample) |
| CN (1) | CN109379891B (enExample) |
| AU (1) | AU2017273136B2 (enExample) |
| BR (1) | BR112018073521B1 (enExample) |
| CA (1) | CA3025720A1 (enExample) |
| DK (1) | DK3464265T3 (enExample) |
| ES (1) | ES2927779T3 (enExample) |
| GB (1) | GB201609607D0 (enExample) |
| HR (1) | HRP20221019T1 (enExample) |
| HU (1) | HUE059165T2 (enExample) |
| IL (1) | IL263222B (enExample) |
| LT (1) | LT3464265T (enExample) |
| MA (1) | MA45130B1 (enExample) |
| MD (1) | MD3464265T2 (enExample) |
| MX (1) | MX386113B (enExample) |
| PL (1) | PL3464265T3 (enExample) |
| PT (1) | PT3464265T (enExample) |
| RS (1) | RS63604B1 (enExample) |
| RU (1) | RU2756273C2 (enExample) |
| SI (1) | SI3464265T1 (enExample) |
| SM (1) | SMT202200341T1 (enExample) |
| WO (1) | WO2017208005A1 (enExample) |
| ZA (1) | ZA201808638B (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI636047B (zh) | 2013-08-14 | 2018-09-21 | 英商卡爾維斯塔製藥有限公司 | 雜環衍生物 |
| GB201421083D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| RS60600B1 (sr) | 2016-05-31 | 2020-08-31 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609603D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) * | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| IL274557B2 (en) | 2017-11-29 | 2024-09-01 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibitor |
| KR20200143376A (ko) | 2018-03-13 | 2020-12-23 | 샤이어 휴먼 지네틱 테라피즈 인크. | 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도 |
| GB201910125D0 (en) * | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
| WO2021055589A1 (en) | 2019-09-18 | 2021-03-25 | Shire Human Genetic Therapies, Inc. | Heteroaryl plasma kallikrein inhibitors |
| ES2987744T3 (es) | 2019-09-18 | 2024-11-18 | Takeda Pharmaceuticals Co | Inhibidores de calicreína plasmática y usos de los mismos |
| CN111875557B (zh) * | 2020-08-19 | 2023-06-02 | 南通大学 | 一种噻唑类衍生物及其合成方法 |
| WO2022084693A1 (en) * | 2020-10-23 | 2022-04-28 | Kalvista Pharmaceuticals Limited | Treatments of angioedema |
| WO2022172006A1 (en) * | 2021-02-09 | 2022-08-18 | Kalvista Pharmaceuticals Limited | Treatments of hereditary angioedema |
| EP4673437A1 (en) | 2023-02-27 | 2026-01-07 | Kalvista Pharmaceuticals Limited | New solid form of a plasma kallikrein inhibitor |
Family Cites Families (111)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
| GB9019558D0 (en) | 1990-09-07 | 1990-10-24 | Szelke Michael | Enzyme inhibitors |
| SE9301911D0 (sv) | 1993-06-03 | 1993-06-03 | Ab Astra | New peptide derivatives |
| US5589467A (en) | 1993-09-17 | 1996-12-31 | Novo Nordisk A/S | 2,5',N6-trisubstituted adenosine derivatives |
| US5786328A (en) | 1995-06-05 | 1998-07-28 | Genentech, Inc. | Use of kunitz type plasma kallikrein inhibitors |
| US7101878B1 (en) | 1998-08-20 | 2006-09-05 | Agouron Pharmaceuticals, Inc. | Non-peptide GNRH agents, methods and intermediates for their preparation |
| PT1169038E (pt) | 1999-04-15 | 2012-10-26 | Bristol Myers Squibb Co | Inibidores cíclicos da proteína tirosina cinase |
| JP2003516414A (ja) | 1999-12-08 | 2003-05-13 | ファルマシア コーポレイション | より高い溶解速度を示すエプレレノン結晶形 |
| ATE355064T1 (de) | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| DE60235114D1 (de) | 2001-11-01 | 2010-03-04 | Icagen Inc | Pyrazolamide zur anwendung in der behandlung von schmerz |
| GB0205527D0 (en) | 2002-03-08 | 2002-04-24 | Ferring Bv | Inhibitors |
| AU2003230829B8 (en) | 2002-04-26 | 2008-12-11 | Eli Lilly And Company | Triazole derivatives as tachykinin receptor antagonists |
| EP1426364A1 (en) | 2002-12-04 | 2004-06-09 | Aventis Pharma Deutschland GmbH | Imidazole-derivatives as factor Xa inhibitors |
| DE10301300B4 (de) | 2003-01-15 | 2009-07-16 | Curacyte Chemistry Gmbh | Verwendung von acylierten 4-Amidino- und 4-Guanidinobenzylaminen zur Inhibierung von Plasmakallikrein |
| WO2004069792A2 (en) | 2003-02-03 | 2004-08-19 | Janssen Pharmaceutica N.V. | Quinoline-derived amide modulators of vanilloid vr1 receptor |
| AU2004268614C1 (en) | 2003-08-27 | 2010-10-28 | Ophthotech Corporation | Combination therapy for the treatment of ocular neovascular disorders |
| TW200526588A (en) | 2003-11-17 | 2005-08-16 | Smithkline Beecham Corp | Chemical compounds |
| GB0403155D0 (en) | 2004-02-12 | 2004-03-17 | Vernalis Res Ltd | Chemical compounds |
| EP1568698A1 (en) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrole-derivatives as factor Xa inhibitors |
| US7429604B2 (en) | 2004-06-15 | 2008-09-30 | Bristol Myers Squibb Company | Six-membered heterocycles useful as serine protease inhibitors |
| ES2367312T3 (es) | 2004-09-03 | 2011-11-02 | Yuhan Corporation | DERIVADOS DE PIRROLO [3,2-c] PIRIDINA Y PROCESOS PARA LA PREPARACIÓN DE LOS MISMOS. |
| US8841259B2 (en) | 2005-02-24 | 2014-09-23 | Joslin Diabetes Center | Compositions and methods for treating vascular permeability |
| GB0508472D0 (en) | 2005-04-26 | 2005-06-01 | Glaxo Group Ltd | Compounds |
| EA012882B1 (ru) | 2005-04-28 | 2009-12-30 | ДСМ АйПи ЭССЕТС Б.В. | Фармацевтические лекарственные формы, содержащие липидную фазу |
| KR101142363B1 (ko) | 2005-06-27 | 2012-05-21 | 주식회사유한양행 | 피롤로피리딘 유도체를 포함하는 항암제 조성물 |
| KR20080032188A (ko) | 2005-07-14 | 2008-04-14 | 다케다 샌디에고, 인코포레이티드 | 히스톤 탈아세틸화 효소 억제제 |
| US20070254894A1 (en) | 2006-01-10 | 2007-11-01 | Kane John L Jr | Novel small molecules with selective cytotoxicity against human microvascular endothelial cell proliferation |
| GB0606876D0 (en) | 2006-04-05 | 2006-05-17 | Glaxo Group Ltd | Compounds |
| US20070258976A1 (en) | 2006-05-04 | 2007-11-08 | Ward Keith W | Combination Therapy for Diseases Involving Angiogenesis |
| US7718693B2 (en) | 2006-07-06 | 2010-05-18 | Glaxo Group Limited | Receptor antagonists and their methods of use |
| AU2007281220B2 (en) | 2006-07-31 | 2013-08-15 | Activesite Pharmaceuticals, Inc. | Inhibitors of plasma kallikrein |
| DE102006050672A1 (de) | 2006-10-24 | 2008-04-30 | Curacyte Discovery Gmbh | Hemmstoffe des Plasmins und des Plasmakallikreins |
| PT2439205E (pt) | 2006-12-29 | 2015-07-16 | Abbvie Deutschland | Compostos de carboxamida e seus usos como inibidores de calpaína |
| WO2008091692A2 (en) | 2007-01-25 | 2008-07-31 | Joslin Diabetes Center, Inc. | Methods of diagnosing, treating, and preventing increased vascular permeability |
| CA2680173A1 (en) | 2007-03-07 | 2008-09-12 | Alantos Pharmaceuticals Holding, Inc. | Metalloprotease inhibitors containing a heterocyclic moiety |
| SG179437A1 (en) | 2007-03-30 | 2012-04-27 | Sanofi Aventis | Pyrimidine hydrazide compounds as pgds inhibitors |
| CN101679291A (zh) | 2007-04-03 | 2010-03-24 | 葛兰素集团有限公司 | 作为p2x7调节剂的咪唑烷甲酰胺衍生物 |
| CL2008002172A1 (es) | 2007-07-26 | 2008-11-21 | Syngenta Participations Ag | Compuestos derivados de pirazol-etiloxiamidas; compuestos intermediarios; metodo para controlar o prevenir la infestacion de plantas utiles por parte de microorganismos fitopatogenos; y composicion para controlar y proteger contra microorganismos fitopatogenos. |
| WO2009026407A1 (en) | 2007-08-22 | 2009-02-26 | Allergan, Inc. | Pyrrole compounds having sphingosine-1-phosphate receptor agonist or antagonist biological activity |
| US8642660B2 (en) | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| WO2009083553A1 (en) | 2007-12-31 | 2009-07-09 | Rheoscience A/S | Azine compounds as glucokinase activators |
| WO2009097141A1 (en) | 2008-01-31 | 2009-08-06 | Joslin Diabetes Center | Methods for treatment of kallikrein-related disorders |
| WO2009106980A2 (en) | 2008-02-29 | 2009-09-03 | Pfizer Inc. | Indazole derivatives |
| WO2009114677A1 (en) | 2008-03-13 | 2009-09-17 | Bristol-Myers Squibb Company | Pyridazine derivatives as factor xia inhibitors |
| CA2730078A1 (en) | 2008-07-08 | 2010-01-14 | Daiichi Sankyo Company, Limited | Nitrogen-containing aromatic heterocyclyl compound |
| US8324385B2 (en) | 2008-10-30 | 2012-12-04 | Madrigal Pharmaceuticals, Inc. | Diacylglycerol acyltransferase inhibitors |
| GB0910003D0 (en) | 2009-06-11 | 2009-07-22 | Univ Leuven Kath | Novel compounds for the treatment of neurodegenerative diseases |
| JP2013515000A (ja) | 2009-12-18 | 2013-05-02 | アクティベサイト ファーマシューティカルズ インコーポレイティッド | 血漿カリクレインの阻害薬のプロドラッグ |
| JP2011157349A (ja) | 2010-01-07 | 2011-08-18 | Daiichi Sankyo Co Ltd | 含窒素芳香族ヘテロシクリル化合物を含有する医薬組成物 |
| JP5709902B2 (ja) | 2010-01-28 | 2015-04-30 | ザ メディシンズ カンパニー （ライプツィヒ） ゲーエムベーハー | トリプシン様セリンプロテアーゼ阻害剤、ならびにその調製および使用 |
| JP2013121919A (ja) | 2010-03-25 | 2013-06-20 | Astellas Pharma Inc | 血漿カリクレイン阻害剤 |
| ES2483802T3 (es) | 2010-07-07 | 2014-08-07 | The Medicines Company (Leipzig) Gmbh | Inhibidores de serina proteasa |
| EP2595986A2 (en) | 2010-07-14 | 2013-05-29 | Addex Pharma SA | Novel 2-amino-4-pyrazolyl-thiazole derivatives and their use as allosteric modulators of metabotropic glutamate receptors |
| US9290485B2 (en) * | 2010-08-04 | 2016-03-22 | Novartis Ag | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides |
| EP2458315B1 (de) | 2010-11-25 | 2017-01-04 | Balcke-Dürr GmbH | Regenerativer Wärmetauscher mit zwangsgeführter Rotordichtung |
| US8691861B2 (en) | 2011-04-13 | 2014-04-08 | Activesite Pharmaceuticals, Inc. | Prodrugs of inhibitors of plasma kallikrein |
| MX2013013690A (es) * | 2011-06-08 | 2014-01-08 | Micro Motion Inc | Metodo y aparato de determinacion y control de presion de fluido estatico a traves de medidor de vibracion. |
| WO2012174362A1 (en) | 2011-06-17 | 2012-12-20 | Research Triangle Institute | Pyrazole derivatives as cannabinoid receptor 1 antagonists |
| GB2494851A (en) | 2011-07-07 | 2013-03-27 | Kalvista Pharmaceuticals Ltd | Plasma kallikrein inhibitors |
| WO2013048982A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| WO2013049096A1 (en) | 2011-09-27 | 2013-04-04 | Bristol-Myers Squibb Company | Pyrrolinone carboxamide compounds useful as endothelial lipase inhibitors |
| EP2807156A1 (en) | 2012-01-27 | 2014-12-03 | Novartis AG | Aminopyridine derivatives as plasma kallikrein inhibitors |
| WO2013111108A1 (en) * | 2012-01-27 | 2013-08-01 | Novartis Ag | 5-membered heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| WO2013120104A2 (en) | 2012-02-10 | 2013-08-15 | Constellation Pharmaceuticals | Modulators of methyl modifying enzymes, compositions and uses thereof |
| WO2013130603A1 (en) | 2012-02-27 | 2013-09-06 | Board Of Regents, The University Of Texas System | Ganglioside gd2 as a marker and target on cancer stem cells |
| GB201212081D0 (en) | 2012-07-06 | 2012-08-22 | Kalvista Pharmaceuticals Ltd | New polymorph |
| IL239682B (en) * | 2013-01-08 | 2018-10-31 | Kalvista Pharmaceuticals Ltd | History of benzylamine and 2-(aminomethyl)pyridine |
| AU2014204889A1 (en) | 2013-01-08 | 2015-06-11 | European Molecular Biology Laboratory | Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease |
| GB201300304D0 (en) | 2013-01-08 | 2013-02-20 | Kalvista Pharmaceuticals Ltd | Benzylamine derivatives |
| GB2510407A (en) | 2013-02-04 | 2014-08-06 | Kalvista Pharmaceuticals Ltd | Aqueous suspensions of kallikrein inhibitors for parenteral administration |
| IL273688B2 (en) | 2013-01-20 | 2024-12-01 | Dyax Corp | Evaluation and treatment of bradykinin-mediated disorders |
| ES2853483T3 (es) | 2013-03-15 | 2021-09-16 | Verseon Int Corporation | Compuestos aromáticos multisustituidos como inhibidores de la serina proteasa |
| HUE034829T2 (en) | 2013-05-23 | 2018-03-28 | Kalvista Pharmaceuticals Ltd | Heterocyclic derivatives |
| GB2517908A (en) | 2013-08-14 | 2015-03-11 | Kalvista Pharmaceuticals Ltd | Bicyclic inhibitors |
| HUE14755117T2 (hu) | 2013-08-14 | 2018-12-28 | Kalvista Pharmaceuticals Ltd | Plazma-kallikrein inhibitorok |
| WO2015103317A1 (en) | 2013-12-30 | 2015-07-09 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| US9611252B2 (en) | 2013-12-30 | 2017-04-04 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| PL3828173T3 (pl) | 2014-03-07 | 2022-12-19 | Biocryst Pharmaceuticals, Inc. | Podstawiane pirazole jako inhibitory ludzkiej kalikreiny osoczowej |
| WO2015171527A1 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Pyrazolopyridine pyrazolopyrimidine and related compounds |
| WO2015171526A2 (en) | 2014-05-05 | 2015-11-12 | Global Blood Therapeutics, Inc. | Tricyclic pyrazolopyridine compounds |
| MX381342B (es) | 2014-07-16 | 2025-03-12 | Lifesci Pharmaceuticals Inc | Compuestos terapeuticos inhibidores. |
| CA2959026C (en) | 2014-08-22 | 2023-10-24 | Biocryst Pharmaceuticals, Inc. | Compositions and uses of amidine derivatives |
| BR112017004704A2 (pt) | 2014-09-17 | 2018-01-23 | Verseon Corp | composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio em um indivíduo |
| GB201421085D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| GB201421083D0 (en) * | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | Enzyme inhibitors |
| GB201421088D0 (en) | 2014-11-27 | 2015-01-14 | Kalvista Pharmaceuticals Ltd | New enzyme inhibitors |
| US10532995B2 (en) | 2015-02-27 | 2020-01-14 | Verseon Corporation | Substituted pyrazole compounds as serine protease inhibitors |
| EP3317241A4 (en) | 2015-07-01 | 2019-01-23 | Lifesci Pharmaceuticals, Inc. | THERAPEUTIC INHIBITING COMPOUNDS |
| CA2991171A1 (en) | 2015-07-01 | 2017-01-05 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| WO2017072020A1 (en) | 2015-10-27 | 2017-05-04 | Boehringer Ingelheim International Gmbh | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| EP3368524B1 (en) | 2015-10-27 | 2021-08-18 | Boehringer Ingelheim International GmbH | Heteroarylcarboxamide derivatives as plasma kallikrein inhibitors |
| RS60600B1 (sr) | 2016-05-31 | 2020-08-31 | Kalvista Pharmaceuticals Ltd | Derivati pirazola kao inhibitori kalikreina plazme |
| GB201609519D0 (en) | 2016-05-31 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of n-[(2,6-difluoro-3-methoxyphenyl)methyl]-3-(methoxymethyl)-1-({4-[(2-oxopyr idin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609602D0 (en) | 2016-06-01 | 2016-07-13 | Nucuna Biomed Ltd | Chemical compounds |
| GB201609603D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-[(6-cyano-2-fluoro-3-methoxyphenyl)Methyl]-3-(methoxymethyl)-1-({4-[(2-ox opyridin-1-YL)Methyl]phenyl}methyl)pyrazole-4-carboxamide |
| GB201609607D0 (en) | 2016-06-01 | 2016-07-13 | Kalvista Pharmaceuticals Ltd | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts |
| GB201609601D0 (en) | 2016-06-01 | 2016-07-13 | Nucana Biomed Ltd | Phosphoramidate compounds |
| WO2018011628A1 (en) | 2016-07-11 | 2018-01-18 | Lifesci Pharmaceuticals, Inc. | Therapeutic inhibitory compounds |
| GB201713660D0 (en) | 2017-08-25 | 2017-10-11 | Kalvista Pharmaceuticals Ltd | Pharmaceutical compositions |
| WO2019106359A1 (en) | 2017-11-29 | 2019-06-06 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| GB201719882D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of a plasma kallikrein inhibitor and salts thereof |
| GB201721515D0 (en) | 2017-12-21 | 2018-02-07 | Kalvista Pharmaceuticals Ltd | Dosage forms comprising a plasma kallikrein inhibtor |
| GB201719881D0 (en) | 2017-11-29 | 2018-01-10 | Kalvista Pharmaceuticals Ltd | Solid forms of plasma kallikrein inhibitor and salts thereof |
| GB201910116D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of hereditary angioedema |
| GB201910125D0 (en) | 2019-07-15 | 2019-08-28 | Kalvista Pharmaceuticals Ltd | Treatments of angioedema |
| CN114206852A (zh) | 2019-08-09 | 2022-03-18 | 卡尔维斯塔制药有限公司 | 血浆激肽释放酶抑制剂 |
| BR112022001054A2 (pt) | 2019-08-21 | 2022-03-15 | Kalvista Pharmaceuticals Ltd | Inibidores enzimáticos |
| EP4017850A1 (en) | 2019-08-21 | 2022-06-29 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| AU2019462140A1 (en) | 2019-08-21 | 2022-02-24 | Kalvista Pharmaceuticals Limited | Enzyme inhibitors |
| CN114269430A (zh) | 2019-08-21 | 2022-04-01 | 卡尔维斯塔制药有限公司 | 酶抑制剂 |
| GB201918994D0 (en) | 2019-12-20 | 2020-02-05 | Kalvista Pharmaceuticals Ltd | Treatments of diabetic macular edema and impaired visual acuity |
-
2016
- 2016-06-01 GB GBGB1609607.5A patent/GB201609607D0/en not_active Ceased
-
2017
- 2017-06-01 MA MA45130A patent/MA45130B1/fr unknown
- 2017-06-01 DK DK17728614.3T patent/DK3464265T3/da active
- 2017-06-01 IL IL263222A patent/IL263222B/en unknown
- 2017-06-01 BR BR112018073521-3A patent/BR112018073521B1/pt active IP Right Grant
- 2017-06-01 LT LTEPPCT/GB2017/051579T patent/LT3464265T/lt unknown
- 2017-06-01 EP EP22183889.9A patent/EP4151630A1/en active Pending
- 2017-06-01 US US16/303,334 patent/US11230537B2/en active Active
- 2017-06-01 RU RU2018139276A patent/RU2756273C2/ru active
- 2017-06-01 WO PCT/GB2017/051579 patent/WO2017208005A1/en not_active Ceased
- 2017-06-01 CA CA3025720A patent/CA3025720A1/en active Pending
- 2017-06-01 HU HUE17728614A patent/HUE059165T2/hu unknown
- 2017-06-01 RS RS20220860A patent/RS63604B1/sr unknown
- 2017-06-01 PL PL17728614.3T patent/PL3464265T3/pl unknown
- 2017-06-01 JP JP2018559929A patent/JP6957516B2/ja active Active
- 2017-06-01 AU AU2017273136A patent/AU2017273136B2/en active Active
- 2017-06-01 ES ES17728614T patent/ES2927779T3/es active Active
- 2017-06-01 SM SM20220341T patent/SMT202200341T1/it unknown
- 2017-06-01 CN CN201780034393.XA patent/CN109379891B/zh active Active
- 2017-06-01 MD MDE20190411T patent/MD3464265T2/ro unknown
- 2017-06-01 HR HRP20221019TT patent/HRP20221019T1/hr unknown
- 2017-06-01 SI SI201731201T patent/SI3464265T1/sl unknown
- 2017-06-01 EP EP17728614.3A patent/EP3464265B1/en active Active
- 2017-06-01 PT PT177286143T patent/PT3464265T/pt unknown
- 2017-06-01 MX MX2018014700A patent/MX386113B/es unknown
- 2017-06-01 KR KR1020187038208A patent/KR102425918B1/ko active Active
-
2018
- 2018-12-20 ZA ZA2018/08638A patent/ZA201808638B/en unknown
-
2021
- 2021-10-06 JP JP2021164519A patent/JP7383676B2/ja active Active
- 2021-10-20 US US17/505,906 patent/US11739068B2/en active Active
-
2023
- 2023-07-06 US US18/347,815 patent/US20240199573A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019517463A5 (enExample) | ||
| RU2018139276A (ru) | Полиморфные модификации n-[(3-фтор-4-метоксипиридин-2-ил)метил]-3-(метоксиметил)-1-({ 4-[(2-оксопиридин-1-ил)метил]фенил} метил)пиразол-4-карбоксамида и их соли | |
| JP2021504310A5 (enExample) | ||
| RU2020121150A (ru) | Твердые формы ингибитора калликреина плазмы и его солей | |
| JP2015528798A5 (enExample) | ||
| RU2020121152A (ru) | Твердые формы ингибитора калликреина плазмы и их соли | |
| CN104837833B (zh) | Xia因子抑制剂的晶型 | |
| JP5566907B2 (ja) | Ｎ−（ｔｅｒｔ−ブトキシカルボニル）−３−メチル−ｌ−バリル−（４ｒ）−４−（（７−クロロ−４−メトキシ−１−イソキノリニル）オキシ）−ｎ−（（１ｒ，２ｓ）−１−（（シクロプロピルスルホニル）カルバモイル）−２−ビニルシクロプロピル）−ｌ−プロリンアミドの結晶フォーム | |
| JP2020518581A5 (enExample) | ||
| JP2020183408A (ja) | ｛［５−（３−クロロフェニル）−３−ヒドロキシピリジン−２−カルボニル］アミノ｝酢酸の固体形態、組成物、及びその使用 | |
| JP2019135258A (ja) | 第Ｘａ因子阻害剤の結晶形態 | |
| JP2019509268A5 (enExample) | ||
| JP2021512114A5 (enExample) | ||
| JP2016505071A5 (enExample) | ||
| TW201028428A (en) | Process for producing diamine derivatives | |
| JP2009534373A5 (enExample) | ||
| JP2018509426A5 (enExample) | ||
| CN103108874A (zh) | 用于制备双嘧达莫的方法 | |
| CN104086544B (zh) | 阿哌沙班一水合物及其制备方法和药物组合物 | |
| JPWO2020111268A5 (enExample) | ||
| CN103408400B (zh) | 一种肌醇晶体及其制备方法和用途 | |
| JP2017514867A5 (enExample) | ||
| EP3209661B1 (en) | Process for preparing a polymorph of rivaroxaban | |
| WO2016127898A1 (zh) | 一种化合物的a晶型及其制备方法 | |
| JP2003535082A (ja) | 非晶性オキサゾール化合物およびシクロオキシゲナーゼ−２（ｃｏｘ−２）阻害剤としてのその使用 |